Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-1001 in STEMI Undergoing Primary PCI
NCT00271765Phase 2Completed
- Sponsor
- Inotek Pharmaceuticals
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial in ST elevation myocardial infarction (STEMI) comparing INO-1001 with Placebo (2 arms). Primary endpoint: Safety of INO-1001. Started Jan 2004; status: completed.
02
Drugs
INO-1001
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT00271765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271765.